![]() |
Volumn 349, Issue , 2014, Pages g6904-
|
European ombudsman questions European Medicines Agency over AbbVie redactions
a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ADALIMUMAB;
MONOCLONAL ANTIBODY;
CLINICAL TRIAL (TOPIC);
DRUG APPROVAL;
DRUG CONTROL;
DRUG INDUSTRY;
EUROPEAN UNION;
HUMAN;
INTERPERSONAL COMMUNICATION;
LEGISLATION AND JURISPRUDENCE;
ORGANIZATION AND MANAGEMENT;
POSTMARKETING SURVEILLANCE;
PUBLISHING;
ANTIBODIES, MONOCLONAL, HUMANIZED;
CLINICAL TRIALS AS TOPIC;
DISCLOSURE;
DRUG AND NARCOTIC CONTROL;
DRUG APPROVAL;
DRUG INDUSTRY;
EUROPEAN UNION;
HUMANS;
PRODUCT SURVEILLANCE, POSTMARKETING;
PUBLISHING;
|
EID: 84925582285
PISSN: None
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.g6904 Document Type: Note |
Times cited : (1)
|
References (0)
|